



4-11-07

EXPRESS MAIL NO.: EV473970979US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rabbani et al.

Confirmation No.: 7704

Application No.: 10/687,554

Art Unit: 1642

Filed: October 15, 2003

Examiner: Yao, Lei

For: UROKINASE PLASMINOGEN
ACTIVATOR RECEPTOR AS A
TARGET FOR DIAGNOSIS OF
METASTASES

Attorney Docket No.: 9471-019-999
CAM No.: 209025-999018

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **A01-A11**; **B01-B07** and **C01-C29**, listed on the attached form entitled "List of References Cited by Applicant." Legible copies of references B01-B07 and C01-C29 are submitted herewith as a hardcopy as well as in a diskette.

Copies of references A01-A11 are not submitted herewith because they are U.S. patent that have been stored in the IFW system of United States Patent and Trademark Office. Pursuant to 37 C.F.R. §1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the

foregoing references and that the references be made of record in the file history of the application.


Pursuant to 37 C.F.R. §1.97 (b)(3), Applicants estimates that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: April 9, 2007

Nikolaos C. George 39,201
Nikolaos C. George (Reg. No.)

Susie S. Cheng 46,616
By: Susie S. Cheng (Reg. No.)
JONES DAY
222 East 41st Street
New York, N.Y. 10017-6702
212-326-3939



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 9471-019-999	APPLICATION NO. 10/687,554
APPLICANT Rabbani et al.	
FILING DATE October 15, 2003	ART UNIT 1642

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	A01	4,782,840	11/8/88	Martin Jr. et al.	
	A02	5,015,571	05/14/91	Niman et al.	
	A03	5,189,014	02/23/93	Cowan Jr.	
	A04	5,225,539	7/6/93	Winter	
	A05	5,383,456	1/24/95	Arnold et al.	
	A06	5,441,050	8/15/95	Thurston et al.	
	A07	5,519,120	5/21/96	Dano et al.	
	A08	5,532,132	07/02/96	Wang Ning et al.	
	A09	5,585,089	12/17/96	Queen	
	A10	5,679,350	10/21/97	Jankun et al.	
	A11	6,077,508	6/20/00	Rabbani et al.	

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
	B01	EP 0 691 350	1/10/96	Boehringer Mannheim GMBH Cancerforskningsfondet		
	B02	UK 2,246,779	2/12/92	Delta Biotechnology Limited		
	B03	WO 92/02553	2/20/92	Delta Biotechnology Limited Balance		
	B04	WO 92/07083	04/30/92	Cancerforskningsfondet AF		
	B05	WO 93/09808	05/27/93	University of Michigan		
	B06	WO 94/28145	12/08/94	Chiron Corporation		
	B07	WO 95/04281	02/09/95	NASA		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
	C01	ACHBAROU et al., 1994, "Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo." Cancer Res. 54:2372-2377	
	C02	ANDREASEN et al., 1997, "The Urokinase-Type Plasminogen Activator System in Cancer Metastasis: A Review." Int. J. Cancer 72:1-22	
	C03	APPELLA et al., 1987, "The Receptor-Binding Sequence of Urokinase." J. Biol. Chem. 262:4437-4440	
	C04	CHUCHOŁOWSKI et al., 1992, "Flow Cytofluorometric Analysis of the Urokinase Receptor (uPAR) on Tumor Cells by Fluorescent uPA-Ligand or Monoclonal Antibody #3936." Fibrinolysis 6(suppl 4):95-102	

NYI-3976412v1

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9471-019-999	APPLICATION NO. 10/687,554
	APPLICANT Rabbani et al.	
	FILING DATE October 15, 2003	ART UNIT 1642

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
	C05	CICCOCIO PPO et al., 1997, "Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA." J. Histochem. & Cytochem, 45(9):1307-1313	
	C06	CROWLEY et al., 1993, "Prevention of metastasis by inhibition of the urokinase receptor." Proc. Nat. Acad Sci USA 90(1):5021-5025	
	C07	DEVRIES et al., 1994, "Plasminogen Activators, Their Inhibitors, and Urokinase Receptor Emerge in Late Stages of Melanocytic Tumor Progression." Am. J. Path. 144:70-81	
	C08	HAQ et al., 1993, "A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo." J. Clin. Invest 91:2416-2422	
	C09	JANKUN, 1993, "The Urokinase Plasminogen Activator Pathway as Novel Mechanism of Tumor Targeting and Cell Membrane Traversal." J. Cell. Biochem. Suppl(17C):33 (Abstract H 242)	
	C10	JANKUN et al., 1993, "Expression and Localization of Elements of the Plasminogen Activator System in Benign Breast Disease and Breast Cancers." J. Cell. Biochem. 53:135-144	
	C11	LAU et al., 1995, "Increase of Urokinase Receptor-related Low-molecular-weight molecule in colorectal Adenocarcinomas." Clin & Exper. Metastasis 13(6): 492-498	
	C12	LIOTTA et al., 1986, "Tumor Invasion and Metastases - Role of the Extracellular Matrix: Rhoads Memorial Award Lecture." Cancer Res. 46:1-7	
	C13	LIOTTA et al., 1991, "Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation." Cell 64:327-336	
	C14	LUTHER et al., 1997, "Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue." Amer. J. Path. 150(4):1231-1244	
	C15	MORRISON et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains." Proc. Natl. Acad. Sci. 81:6851-6855	
	C16	MUNDY, 1997, "Mechanisms of Bone Metastasis." Cancer (suppl.) 80:1546-1556	
	C17	PARHAM, 1983, "On the fragmentation of monoclonal IgG1, IgG2a and IgG2b from Balb/c mice." J. Immunol. 131:2895-2902	
	C18	PRESTA et al., 1997, "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders." Cancer Res. 57: 4593-4599	
	C19	PYKE et al., 1995, "Lamin-5 is a Marker of Invading Cancer Cells in Some Human Carcinomas and is Coexpressed with the Receptor of Urokinase Plasminogen Activator in Budding Cancer Cells in Colon Adenocarcinomas." Cancer Res. 55:4132-4139.	
	C20	RABBANI et al., 1992, "Structural Requirements for the Growth Factor Activity of the Amino-Terminal Domain of Urokinase." J. Biol. Chem. 267:14151-14156	
	C21	RABBANI et al., 1994, "Isolation and Characterization of Multiple Isoforms of the Rat Urokinase Receptor in Osteoblasts." FEBS Letter, 338:69-74	
	C22	RABBANI, 1997, "Urokinase Receptor Directed Immunodiagnostic and Immunotherapeutic Strategies for Prostate and Breast Cancer." Proc. Am. Assoc. Cancer Res 38:2419 (Abstr. 1673)	
	C23	RIECHMANN et al., 1988, "Reshaping human antibodies for therapy." Nature. 332:323-327	
	C24	RONNE et al., 1991, "Cell -Induced Potentiation of the Plasminogen Activation System is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor." FEBS Letters. 288(1,2):233-236.	
	C25	SCHMITT et al., 1997, "Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy." Thrombosis and Haemostasis 78:285-296	
	C26	WILL et al., 1994, "Expression of Urokinase-type Plasminogen Activator (uPA) and Its Receptor (uPAR) in	

NYI-3976412v1

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

9471-019-999

APPLICATION NO.

10/687,554

APPLICANT

Rabbani et al.

FILING DATE

October 15, 2003

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
		Human Ovarian Cancer Cells and <i>in vitro</i> Invasion Capacity." Intl. J. Oncology 5:753-761	
	C27	WILLNER et al., 1993, "(6-Maleimidocaproyl) hydrazone of Doxorubicin-A new derivative for the preparation of Immunoconjugates of Doxorubicin." Bioconjugate Chem., 4(6):521-7	
	C28	XING AND RABBANI, 1996, "Overexpression of Urokinase Receptor in Breast Cancer Cells Results in Increased Tumor Invasion, Growth and Metastasis." Int. J. Cancer 67:423-429	
	C29	XING AND RABBANI, 1996, "Role of Urokinase Receptor in Breast Cancer Invasion and Metastasis: Potential Therapeutic Strategies." Proc. Am. Assoc. Cancer Res. 37:90 (abstr. 626)	

NYI-3976412v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.